We Offer Worldwide Shipping
Login Wishlist



  • Brand : BIOFRON

  • Catalogue Number : BN-O1592

  • Specification : 98%(HPLC)

  • CAS number : 41447-16-9

  • Formula : C9H19NO

  • Molecular Weight : 157.3

  • PUBCHEM ID : 10888171

  • Volume : 5mg

Available on backorder

Checkout Bulk Order?

Catalogue Number


Analysis Method





Molecular Weight




Botanical Source

This product is isolated and purified from the herbs of Sedum sarmentosum

Structure Type





2-Piperidineethanol, α,1-dimethyl-, (αS,2R)-/N-methylallosedridine/(2S)-1-[(2R)-1-Methyl-2-piperidinyl]-2-propanol



0.9±0.1 g/cm3


Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

81.7±18.5 °C

Boiling Point

223.3±13.0 °C at 760 mmHg

Melting Point


InChl Key


WGK Germany


HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:41447-16-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.




Secondary haemophagocytic lymphohistiocytosis (sHLH) is a rare life-threatening condition mainly associated with underlying infections, malignancies, and autoimmune or immune-mediated diseases.

To analyse all sHLH cases that were diagnosed and managed under real-world circumstances in our department focusing on the treatment schedule and the outcome.

Prospectively collected data from all adult patients fulfilling the criteria of sHLH who diagnosed and managed from January 1, 2010 to June 1, 2018, in our department of the tertiary care university hospital of Larissa, Greece, were analysed retrospectively (n = 80; 52% male; median age: 55 years). The electronic records and/or written charts of the patients were reviewed for the demographic characteristics, clinical manifestations, underlying causes of sHLH, laboratory parameters, treatment schedule and 30-d-mortality rate. Most of patients had received after consent intravenous γ-immunoglobulin (IVIG) for 5 d (total dose 2 g/kg) in combination with intravenous steroid pulses followed by gradual tapering of prednisolone.

Seventy-five patients (94%) reported fever > 38.5 °C, 47 (59%) had liver or spleen enlargement and 76 (95%) had ferritin > 500 ng/mL including 20 (25%) having considerably high levels (> 10000 ng/mL). Anaemia and thrombocytopenia occurred in 72% and leucopoenia in 47% of them. Underlying infections were diagnosed in 59 patients (74%) as follows: leishmaniasis alone in 15/80 (18.9%), leishmaniasis concurrently with Coxiella Burnetti or non-Hodgkin lymphoma in 2/80 (2.5%), bacterial infections in 14/80 (17.5%) including one case with concurrent non-Hodgkin lymphoma, viral infections in 13/80 (16.3%), fungal infections in 2/80 (2.5%), infections by mycobacteria in 1/80 (1.3%) and unidentified pathogens in 12/80 (15%). Seventy-two patients (90%) had received combination treatment with IVIG and intravenous steroids. Overall, sHLH resolved in 76% of patients, 15% died within the first month but 82.5% of patients were still alive 6 mo after diagnosis. Univariate analysis showed older age, anaemia, thrombocytopenia, low fibrinogen, disseminated intravascular coagulation (DIC), and delay of diagnosis as factors that negatively affected remission. However, multivariate analysis showed low platelets and DIC as the only independent predictors of adverse outcome.

sHLH still carries a remarkable morbidity and mortality. Underlying infections were the major cause and therefore, they should be thoroughly investigated in patients with sHLH. Early recognition and combination treatment with IVIG and corticosteroids seem an efficient treatment option with successful outcome in this life-threatening condition.


Haemophagocytic syndrome, Haemophagocytic lymphohistiocytosis, γ-immunoglobulin, Leishmaniasis, Ferritin


Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions


Sarah Georgiadou, Nikolaos K Gatselis, Aggelos Stefos, Kalliopi Zachou, Konstantinos Makaritsis, Eirini I Rigopoulou, and George N Dalekos

Publish date

2019 Nov 6




Although warfarin therapy reduces stroke incidence in patients with atrial fibrillation (AF), the rate of warfarin use in this population remains low. In 2008, the Medicare Part D program was expanded to pay for medications for Medicare enrollees.

To examine rates and predictors of warfarin use in Medicare Part D beneficiaries with AF.

This population-based retrospective cohort study used claims data from 41,447 Medicare beneficiaries aged 66 and older with at least 2 AF diagnoses in 2007 and at least 1 diagnosis in 2008. All subjects had continuous Medicare Part D prescription coverage in 2008. Statistical analysis using χ2 was used to examine differences in warfarin use by patient characteristics (age, ethnicity, sex, Medicaid eligibility, comorbidities, contraindications to warfarin, and whether they visited a cardiologist or a primary care physician [PCP]), CHADS2 score (congestive heart failure, hypertension, age, diabetes, and stroke or transient ischemic attack; higher scores indicate higher risks of stroke), and geographic regions. Using hierarchical generalized linear models restricted to subjects without warfarin contraindications (n = 34,947), we examined the effect of patient characteristics and geographic regions on warfarin use.

The overall warfarin use rate was 66.8%. The warfarin use rates varied between hospital referral regions, with highest rates in the Midwestern states and lowest rates in the South. The regional variation persisted even after adjustment for patient characteristics. Multivariable analysis showed that the odds of being on warfarin decreased significantly with age and increasing comorbidity, in blacks, and among those with low income. Seeing a cardiologist (OR 1.10; 95% CI 1.05-1.16), having a PCP (OR 1.23; 95% CI 1.17-1.29), and CHADS2 score of 2 or greater (OR 1.09; 95% CI 1.01-1.17) were associated with increased odds of warfarin use.

Warfarin use rates vary by patient characteristics and region, with higher rates among residents of the Midwest and among patients seen by cardiologists and PCPs. Preventing stroke-related disability in AF requires implementation of evidence-based initiatives to increase warfarin use.

Stroke is a leading cause of serious, long-term disabilit


National Utilization Patterns of Warfarin Use in Older Patients with Atrial Fibrillation: A Population-Based Study of Medicare Part D Beneficiaries


Mukaila A Raji, MD, MSc, Matthew Lowery, BSc, Yu-Li Lin, MS, Yong-Fang Kuo, PhD, Jacques Baillargeon, PhD, and James S Goodwin, MD

Publish date

2014 May 2.




Three valid species of Parabembras are recognized: P. curta, P. robinsoni, and the new species P. multisquamata. Parabembras robinsoni from the southwestern Indian Ocean (South Africa to Mozambique) is easily distinguishable from the other species in having eleven spines in the first dorsal fin, a distinct symphyseal knob on the lower jaw, two preocular spines, and a single lachrymal spine. Parabembras multisquamata from the southwestern Pacific (Vanuatu, Papua New Guinea) and the Philippines, and P. curta, known from the northwestern Pacific (southern Japan to South China Sea), are similar in sharing the absence of a symphyseal knob on the lower jaw, the presence of two lachrymal spines, and a single preocular spine, but the former is clearly distinguished from the latter in usually having 10 spines in the first dorsal fin (vs. eight or nine spines in P. curta), 9-11 supraocular spines (vs. 6-8 in P. curta), 40-44 pored lateral line scales (vs. 34-39 in P. curta), and the pectoral fin extending beyond the level of the anus (vs. not reaching to the level of the anus in P. curta).


New species, Parabembras curta, Parabembras multisquamata, Parabembras robinsoni, Papua New Guiana, Philippines, taxonomy, Vanuatu


Taxonomic review of the deep water flathead genus Parabembras with description of the new species Parabembras multisquamata from the western Pacific Ocean (Teleostei, Parabembridae)


Yoshiaki Kai1 and Ronald Fricke2

Publish date


Description :

Empty ...